General

Patel et al., “The Lancet Commission on global mental health and sustainable development”, The Lancet (2018)

Abbott, “COVID’s mental-health toll: how scientists are tracking a surge in depression”, Nature (2021)

Salzer, “National Estimates of Recovery-Remission From Serious Mental Illness”, Psychiatry Online (2018).

Tew et al., “Impact of prior treatment exposure on response to antidepressant treatment in late life” Am J Geriatr Psychiatry (2006)

Sinha, ”New Findings on Biological Factors Predicting Addiction Relapse Vulnerability” (2011)

Psilocybin

Griffiths et al., “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significancer” (2006)

Watts et al., “Patients’ Accounts of Increased ‘Connectedness’ and ‘Acceptance’ After Psilocybin for Treatment-Resistant Depression” (2017)

Griffiths et al, “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer” (2016)

Arketamine

Leal et al., “Intravenous arketamine for treatment-resistant depression: open-label pilot study” (2020)

Chang et al., “Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine”, Pharmacology Biochemistry and Behavior (2019)

N,N-Dimethyltryptamine (DMT)

Argento et al., “Exploring ayahuasca‐assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada” (2019)

Palhano-Fontes et al., “Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression”, PsychoMed (2019)

Ibogaine

Schenberg et al., “Treating drug dependence with the aid of ibogaine: A qualitative study” (2017)

Mash et al., “Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes” (2018)

Etifoxine

Nguyen et al., “Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double‐blind controlled study in general practice” (2006)

N-Acetylcysteine

Hoffer et al., “Protective Effect of N-Acetylcysteine Amide on Blast-Induced Increase in Intracranial Pressure in Rats” (2013)

Depression

Hasler et al., “Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose effect study” (2004)

Cognitive Impairment Associated with Schizophrenia (CIAS)

Charlson et al., “Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study” (2016)

Reichenberg et al., “Neuropsychological Function and Dysfunction in Schizophrenia and Psychotic Affective Disorders” (2009)

Laursen, Nordentoft & Mortensen, “Excess early mortality in schizophrenia” (2014)

Cloutier et al., “The Economic Burden of Schizophrenia in the United States in 2013” (2016)

Substance Use Disorder

Wilson et al., “Drug and opioid-involved overdose deaths – United States, 2017-2018” (2020)

Murphy, “The cost of opioid use disorder and the value of aversion” (2020)

Sinha, “New Findings on Biological Factors Predicting Addiction Relapse Vulnerability” (2011)

Anxiety

DeVane et al., “Anxiety Disorders in the 21st Century: Status, Challenges, Opportunities, and Comorbidity With Depression”, AJMC (2005)

DeMartini et al., “Generalized Anxiety Disorder” (2019)

Traumatic Brain Injury

Georges et al, “Traumatic Brain Injury”, NCBI (2020)

Thurman et al., “Report to Congress: Traumatic Brain Injury in the United States”, CDC (1999)

Hoffer et al., “Repositioning drugs for traumatic brain injury”, Journal of Biomedical Science (2017)

Other

Flanagan & Nichols, “Psychedelics as anti-inflammatory agents” (2018)

Spriggs et al., “Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder” (2020)

Lea et al., “Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders” (2020)

De Gregorio et al., “Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission” (2021)

Moreno et al., “Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder” (2006)

Szabo et al., “The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells” (2016)

Vann Jones & O’Kelly, “Psychedelics as a Treatment for Alzheimer’s Disease Dementia” (2020)

Katchborian-Neto et al., “Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson’s disease” (2020)

Thompson et al., “Psychedelics as a novel approach to treating autoimmune conditions” (2020)

Szabo A., “Psychedelics and immunomodulation: novel approaches and therapeutic opportunities” (2015)

Schindler et al., “Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin” (2020)

Sewell et al., “Response of cluster headache to psilocybin and LSD” (2006)

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on ATAI and innovations in the space.

Email
submit